Abstract:Lung cancer is one of the most common malignancies worldwide. Non-small-cell lung cancer (NSCLC) accounts for more than 80% of lung cancers, shows chemotherapy resistance, metastasis, and relapse. The phosphatidylinositol-3 kinase (PI3K)/Akt pathway has been implicated in the carcinogenesis and disease progression of NSCLC, suggesting that it may be a promising therapeutic target for cancer therapy. Although phenylurea derivatives have been reported as potent multiple kinase inhibitors, novel unsymmetrical N,Nʹ-diarylurea derivatives targeting the PI3K/Akt pathway in NSCLC cells remain unknown. Methods: N,Nʹ-substituted phenylurea derivatives CTPPU and CT-(4-OH)-PU were investigated for their anticancer proliferative activity against three NSCLC cell lines (H460, A549, and H292) by 3-(4,5-dimethythiazol-2-yl)-2,5-diphenyl tetrazolium bromide, colony formation, Hoechst33342/PI staining assays, and apoptosis analysis. The protein expressions of Akt pathway-related proteins in response to CTPPU or CT-(4-OH)-PU were detected by Western blot analysis. The Kyoto Encyclopedia of Genes and Genomes mapper was used to identify the possible signaling pathways in NSCLC treated with CTPPU. The cell cycle was analyzed by flow cytometry. Molecular docking was used to investigate the possible binding interaction of CTPPU with Akt, the mammalian target of rapamycin complex 2 (mTORC2), and PI3Ks. Immunofluorescence and Western blot analysis were used to validate our prediction. Results: The cytotoxicity of CTPPU was two-fold higher than that of CT-(4-OH)-PU for all NSCLC cell lines. Similarly, the non-cytotoxic concentration of CTPPU (25 µM) dramatically inhibited the colony formation of NSCLC cells, whereas its relative analog CT-(4-OH)-PU had no effect. Protein analysis revealed that Akt and its downstream effectors, namely, phosphorylated glycogen synthase kinase (GSK)-3β (Ser9), β-catenin, and c-Myc, were reduced in response to CTPPU treatment, which suggested the targeting of Akt-dependent pathway, whereas CT-(4-OH)-PU had no effect on such cell growth regulatory signals. CTPPU induced G1/S cell cycle arrest in lung cancer cells. Immunofluorescence revealed that CTPPU decreased p-Akt and total Akt protein levels, which implied the effect of the compound on protein activity and stability. Next, we utilized in silico molecular docking analysis to reveal the potential molecular targets of CTPPU, and the results showed that the compound could specifically bind to the allosteric pocket of Akt and three sites of mTORC2 (catalytic site, A-site, and I-site), with a binding affinity greater than that of reference compounds. The compound cannot bind to PI3K, an upstream regulator of the Akt pathway. The effect of CTPPU on PI3K and Akt was confirmed. This finding indicated that the compound could decrease p-Akt but caused no effect on p-PI3K. Conclusions: The results indicate that CTPPU significantly inhibits NSCLC cell proliferation by inducing G1/S cell cycle arrest via the Akt/GSK-3β/c-Myc signaling pathway. Molecular docking revealed that CTPPU could interact with Akt and mTORC2 molecules with a high binding affinity. These data indicate that CTPPU is a potential novel alternative therapeutic approach for NSCLC.

The Newly Synthesized 2-Arylnaphthyridin-4-one, CSC-3436, Induces Apoptosis of Non-Small Cell Lung Cancer Cells by Inhibiting Tubulin Dynamics and Activating CDK1

N,Nʹ-Diarylurea Derivatives (CTPPU) Inhibited NSCLC Cell Growth and Induced Cell Cycle Arrest Through Akt/GSK-3β/c-Myc Signaling Pathway

A Novel Microtubule Inhibitor, Mt3-037, Causes Cancer Cell Apoptosis by Inducing Mitotic Arrest and Interfering with Microtubule Dynamics

A Novel Sulfonamide Agent, MPSP-001, Exhibits Potent Activity Against Human Cancer Cells in Vitro Through Disruption of Microtubule

P3.02c-004 SBI0206965, a Novel Inhibitor of Ulk1, Suppresses Non-Small Cell Lung Cancer Cell Growth Via Modulating Both Autophagy and Apoptosis Pathways: Topic: Targeted Therapy

A Novel Tubulin Inhibitor, 6h, Suppresses Tumor-Associated Angiogenesis and Shows Potent Antitumor Activity Against Non–small Cell Lung Cancers

SKLB316, a Novel Small-Molecule Inhibitor of Cell-Cycle Progression, Induces G2/M Phase Arrest and Apoptosis in Vitro and Inhibits Tumor Growth in Vivo.

Nanomolar concentration of NSC606985, a camptothecin analog, induces leukemic-cell apoptosis through protein kinase Cdelta-dependent mechanisms.

A Novel Camptothecin Derivative 3j Inhibits Nsclc Proliferation Via Induction of Cell Cycle Arrest by Topo I-Mediated DNA Damage.

NSC606985, a novel camptothecin analog, induces apoptosis and growth arrest in prostate tumor cells

Discovery of CLKs inhibitors for the treatment of non-small cell lung cancer

Anti-tumor Selectivity of a Novel Tubulin and HSP90 Dual-Targeting Inhibitor in Non-Small Cell Lung Cancer Models.

The cyclin-dependent kinase inhibitor SNS-032 induces apoptosis in breast cancer cells via depletion of Mcl-1 and X-linked inhibitor of apoptosis protein and displays antitumor activity in vivo

Investigation of Anti-Tumor Mechanisms of K2154: Characterization of Tubulin Isotypes, Mitotic Arrest and Apoptotic Machinery

Synthesis and biological evaluation of novel chalcone derivatives as a new class of microtubule destabilizing agents.

Nanomolar concentration of NSC606985, a camptothecin analog, induces leukemic cell apoptosis through protein kinase Cδ-dependent mechanisms

Abstract 507: HLS-22001 induces G2/M cell cycle arrest and apoptotic cell death via tubulin depolymerization in colon cancer

5-(Furan-2-yl)-4-(3,4,5-trimethoxyphenyl)-3h-1,2-dithiol-3-one Oxime (6f), a New Synthetic Compound, Causes Human FIbrosarcoma HT-1080 Cell Apoptosis by Disrupting Tubulin Polymerisation and Inducing G2/M Arrest.

Discovery and SARs of 5-Chloro-n4-phenyl-n2-(pyridin-2-yl)pyrimidine-2,4-diamine Derivatives As Oral Available and Dual CDK 6 and 9 Inhibitors with Potent Antitumor Activity

Discovery of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine Derivatives As Highly Selective CK2 Inhibitors with Potent Cancer Cell Stemness Inhibition

Skp2 Inhibitor AAA-237 Exerts Anti-Tumor Effect on NSCLC by Inducing Mitochondria-Dependent Apoptosis and Senescence